GlassScriptPhysician profile
Dalia G Galicia
NPI 1235316308
$6,657.00
in general payments reported to CMS, 2019-2025
32 companies · $2,442 in 2025
The $2,442 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $294 · 2021: $490 · 2022: $272 · 2023: $852 · 2024: $1,323 · 2025: $2,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,555 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,555.24 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,050.01 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $508.95 | 2021-2025 | |
| Glaxosmithkline, LLC. | $453.69 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $414.92 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $343.61 | 2019-2025 | Xolair |
| Amgen INC. | $329.49 | 2023-2025 | Tezspire |
| Pfizer INC. | $301.97 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $241.73 | 2019-2025 | |
| Csl Behring | $233.90 | 2019-2025 | Haegarda, Hizentra |
| Ars Pharmaceuticals Operations, INC. | $218.24 | 2025 | Neffy |
| Grifols USA, LLC | $190.51 | 2019-2025 | Xembify |
| Galderma Laboratories, L.P. | $181.72 | 2025 | Nemluvio |
| Takeda Pharmaceuticals U.S.A., INC. | $138.46 | 2023-2025 | Takhzyro, Cuvitru, Hyqvia |
| Sanofi-Aventis U.S. LLC | $127.36 | 2022-2023 | |
| Ionis Pharmaceuticals, INC. | $111.53 | 2025 | Dawnzera |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $110.69 | 2019 | |
| Optinose US, INC. | $107.83 | 2019-2025 | |
| Azurity Pharmaceuticals, INC. | $63.04 | 2025 | Alvesco |
| Pharming Healthcare, INC. | $62.59 | 2023-2025 | Ruconest |
| Kaleo, INC. | $58.83 | 2019-2024 | Auvi-Q |
| Bio Products Laboratory USA, INC. | $55.59 | 2019-2023 | Gammaplex, Coagadex |
| Phathom Pharmaceuticals, INC. | $54.45 | 2025 | Voquezna |
| Biocryst US Sales Co., LLC | $50.49 | 2021-2025 | Orladeyo |
| Organon LLC | $50.29 | 2025 | Vtama |
| Octapharma USA, INC. | $34.25 | 2023 | Cutaquig |
| Alk-Abello, INC | $33.93 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $32.02 | 2024-2025 | Ryaltris |
| Lilly USA, LLC | $29.67 | 2025 | Ebglyss |
| Kedrion Biopharma, INC. | $20.91 | 2025 | Rhogam Ultra-Filtered Plus, Albuked, Koate |
| Cycle Pharmaceuticals INC | $18.90 | 2025 | Sajazir |
| Greer Laboratories, INC. | $15.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalia Galicia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.